14.73 USD
+0.40
2.79%
At close Feb 21, 4:00 PM EST
After hours
14.70
-0.03
0.20%
1 day
2.79%
5 days
-9.63%
1 month
-6.42%
3 months
-19.51%
6 months
-24.27%
Year to date
-14.81%
1 year
-63.52%
5 years
-84.65%
10 years
-54.91%
 

About: Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

Employees: 504

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $7.05M | Put options by funds: $5.68M

2.82% less ownership

Funds ownership: 84.29% [Q3] → 81.47% (-2.82%) [Q4]

9% less funds holding

Funds holding: 140 [Q3] → 127 (-13) [Q4]

11% less capital invested

Capital invested by funds: $177M [Q3] → $157M (-$19.5M) [Q4]

26% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 46

38% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 29

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16.50
12%
upside
Avg. target
$16.50
12%
upside
High target
$16.50
12%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
DA Davidson
Linda Bolton Weiser
30% 1-year accuracy
34 / 112 met price target
12%upside
$16.50
Neutral
Maintained
19 Feb 2025

Financial journalist opinion

Based on 5 articles about MED published over the past 30 days

Neutral
Zacks Investment Research
2 days ago
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Neutral
Seeking Alpha
3 days ago
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 days ago
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Neutral
Business Wire
3 days ago
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of.
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
Neutral
Business Wire
2 weeks ago
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie.
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
Neutral
Zacks Investment Research
1 month ago
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
Neutral
Zacks Investment Research
1 month ago
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
Neutral
Business Wire
1 month ago
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE:MED), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle hea.
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off
Neutral
Business Wire
2 months ago
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessar.
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
Positive
Zacks Investment Research
3 months ago
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
Charts implemented using Lightweight Charts™